T2 Biosystems And Canon U.S. Life Sciences Announce Joint Collaboration To Develop Novel Test Panel To Rapidly Detect Lyme Disease

T2 Biosystems, Inc. (Nasdaq:TTOO) a company developing innovative diagnostic products to improve patient health today announced that the company has entered into a multi-year, strategic agreement with Canon U.S. Life Sciences, Inc. to jointly develop a novel diagnostic test panel to rapidly detect Lyme disease, a tick-borne bacterial infection that, if left untreated, can cause chronic joint inflammation, neurological disorders and cognitive defects.
Source: Medical Design Online News - Category: Medical Equipment Source Type: news